Study of utidelone and capecitabine versus taxane and capecitabine for breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a new chemotherapy combination (utidelone plus capecitabine) versus a standard taxane plus capecitabine for HER2-negative breast cancer. The goal is to see if the new combo works better and has fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 years or older.
- Your breast cancer must be HER2-negative (a specific protein test result).
- Your cancer must be locally advanced or metastatic (it has spread).
- You can have had no more than one previous chemotherapy for advanced breast cancer.
- You must be able to take oral medication and have normal organ function.
- If you have brain metastases, they must be stable and not causing symptoms.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares utidelone with docetaxel in people with HER2-negative advanced or metastatic breast cancer. It aims to see which treatment works better and is safer for controlling the cancer and helping patients live longer.
This trial looks at whether adding a chemotherapy medicine called capecitabine (taken in smaller, regular doses) to the standard after-surgery (adjuvant) treatment can lower the chance of cancer coming back in people with early-stage, high-risk HER2-positive breast cancer. It targets patients who still had cancer left after earlier treatment or who had higher-risk tumor features.
This trial tests if the combination of Utidelone and capecitabine can shrink brain metastases in people with HER2-negative breast cancer. It is designed for those whose cancer has spread to the brain and who have not had many prior treatments.
This trial tests a combination of two oral chemotherapy drugs (Utidelone and Capecitabine) for women with triple-negative breast cancer that did not fully disappear after standard chemo before surgery. The goal is to see if this treatment can lower the chance of the cancer coming back.
This study tests whether adding utidelone (an investigational drug) to capecitabine (a standard chemo pill) after surgery can reduce the chance of breast cancer returning in patients with triple-negative breast cancer who still had cancer cells after neoadjuvant chemotherapy. Participation could help improve your treatment plan to lower the risk of recurrence.
This trial compares an oral capsule form of the experimental drug Utidelone with the standard injection form, in people with HER2-negative advanced breast cancer. The goal is to see if the capsule works as well as the injection and is safe to use.
Hear when a new Breast Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.